Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pileri

Showing results (861-870 of 992) with videos related to

Pageof 100
Sort By:
Haematologica|March 9, 2010
The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivationTeresa Marafioti, Jennifer C Paterson, Erica Ballabio, et al.
Nature Communications|June 13, 2022
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccineesEmanuele Andreano, Ida Paciello, Silvia Marchese, et al.
The Journal of Pathology|November 14, 2008
A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glandsE Chanudet, H Ye, J Ferry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Leukemia & Lymphoma|February 17, 2018
Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapyRoberta Burnelli, Simona Rinieri, Roberto Rondelli, et al.
Haematologica|October 16, 2012
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter studyLivio Pagano, Caterina Giovanna Valentini, Alessandro Pulsoni, et al.
Pathologica|September 8, 2012
Expression of the CD2AP adaptor molecule in normal, reactive and neoplastic human tissueH Rizvi, J C Paterson, S Tedoldi, et al.
Blood Advances|February 22, 2023
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCLSaveria Mazzara, Laura Travaini, Francesca Botta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2011
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphomaP L Zinzani, M Tani, A Pulsoni, et al.
Pageof 100

Showing results (861-870 of 992) with videos related to

Sort By:
Pageof 100
Haematologica|March 9, 2010
The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivationTeresa Marafioti, Jennifer C Paterson, Erica Ballabio, et al.
Nature Communications|June 13, 2022
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccineesEmanuele Andreano, Ida Paciello, Silvia Marchese, et al.
The Journal of Pathology|November 14, 2008
A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glandsE Chanudet, H Ye, J Ferry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyEmanuele Zucca, Annarita Conconi, Daniele Laszlo, et al.
Leukemia & Lymphoma|February 17, 2018
Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapyRoberta Burnelli, Simona Rinieri, Roberto Rondelli, et al.
Haematologica|October 16, 2012
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter studyLivio Pagano, Caterina Giovanna Valentini, Alessandro Pulsoni, et al.
Pathologica|September 8, 2012
Expression of the CD2AP adaptor molecule in normal, reactive and neoplastic human tissueH Rizvi, J C Paterson, S Tedoldi, et al.
Blood Advances|February 22, 2023
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCLSaveria Mazzara, Laura Travaini, Francesca Botta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor projectMassimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2011
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphomaP L Zinzani, M Tani, A Pulsoni, et al.
Pageof 100